CONMED Corporation (CNMD)

Over the past six months, CONMED Corp.'s stock price has declined significantly. Key events impacting the stock price include the announcement of a strategic exit from its gastroenterology product lines in December 2025, presentation at the 44th Annual J.P. Morgan Healthcare Conference in January 2026, a Chief Financial Officer transition, and the announcement of Fourth Quarter and Full-Year 2025 Financial Results. In April 2026, CONMED CEO Pat Beyer was awarded $1M in RSUs vesting over 3 years and news regarding board moves, CEO pay, and buybacks at CONMED was released. CONMED Corporation is scheduled to announce its First Quarter 2026 Financial Results on April 29, 2026.

CONMED Corporation Common Stock exhibits seasonal tendencies based on 27 years of historical data. December has been the strongest month for CONMED's stock, while July tends to be the weakest month. Over the full calendar year, CONMED Common Stock has an average annual return of 6.69%. The consistency score for this seasonal pattern is considered "Poor".

CONMED Corporation is a medical technology company specializing in surgical devices and equipment for minimally invasive procedures, operating in the healthcare sector. Its business is divided into Orthopedic Surgery, which focuses on sports medicine injuries and minimally invasive joint surgeries, and General Surgery, which offers advanced surgical and endoscopic technology products. CONMED focuses on minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair, and intends to exit its gastroenterology product lines.

CONMED Corporation has a global presence, operating in approximately 100 countries with headquarters in Largo, Florida. It has manufacturing facilities in the United States and Mexico, along with international offices. Its products are distributed through sales subsidiaries and branches in numerous countries, with the majority of revenue generated from the United States.

CONMED embraces a "people-first culture" with a mission to support its healthcare partners and the patients they serve. There were no specific events in the past year that significantly impacted CONMED Corp.'s brand reputation, either positively or negatively, mentioned in the provided search results. The company's strategic exit from gastroenterology product lines in December 2025 could be seen as a portfolio optimization strategy.

CONMED Corporation's stock is predominantly held by institutional investors. As of April 9, 2026, institutional shareholders own 110.23% of CONMED stock, Conmed insiders own 3.20%, and retail investors own 0.00%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Earnest Partners Llc.